Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

British Journal of Cancer

Volumn 89, Issue 4, 2003, Pages 634-640

  Gordois, A ^a   Scuffham, P ^a   Warren, E ^b   Ward, S ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Chemotherapy; Cost effectiveness; Economic evaluation; Glivec

Indexed keywords

ARABINOSIDE; CYTARABINE; DAUNORUBICIN; IMATINIB; TIOGUANINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MARKOV CHAINS; PIPERAZINES; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE;

EID: 0041733714     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601151     Document Type: Article

References (26)

1. Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345: 1392-1397
2. Beck JR, Pauker SG (1983) The Markov process in medical prognosis. Med Decis Making 3: 419-458
3. Bogard B, Scheer D (2001) Imatinib STI571: A Recommended Pharmacoeconomic Strategy, HPM201b Final Project, Camberley: Novartis Pharma
4. British National Formulary (2001) BNF 41 March 2001. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain
5. Capdeville R, Gathmann I (2001) Integrated summary of efficacy-Update (cut-off 31-Jan-01). Basel: Novartis Pharma AG
6. Department of Health (2002) NHS Reference Costs 2001. London: Department of Health
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001a) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (14): 1031-1037
8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001b) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (14): 1038-1042
9. Gorin NC (1998) Autologous stem cell transplantation in acute myelocytic leukemia. Blood 92: 1073-1090
10. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S., Talpaz M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122: 254-261
11. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FL, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. (2002) Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesilate. Clin Cancer Res 8 (7): 2167-2176
12. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR (1996) Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 125: 541-548
13. Kolibaba KS, Druker BJ (2000) Current status of treatment for chronic myelogenous leukaemia. Medscape Hematology-Oncology eJournal, 3, http://www.medscape.com/viewarticle/408451 (Last checked 21 May 2002)
14. Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC (1998) The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 92: 4047-4052
15. Liberato NL, Quaglini S, Barosi G (1997) Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 15: 2673-2682
16. Messori A (1998) Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 9: 389-396
17. National Institute for Clinical Excellence (2001) Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal. London: National Institute for Clinical Excellence
18. Netten A, Rees T, Harrison G (2002) Unit Costs of Health and Social Care 2001. Personal Social Services Research Unit. University of Kent: Cantebury
19. O'Brien S (2000) MIMS Guide to Chronic Myeloid Leukaemia. Medical Imprint, London
20. Reese SF, Wehrle E, Gathmann I (2000) A Phase III Study of STI571 Versus Interferon-alpha Combined with Cytarabine in Patients with Newly Diagnosed Previously Untreated Philadelphia Chromosone Positive Chronic Myelogenous Leukaemia in Chronic Phase (protocol). Basel: Novartis AG
21. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340
22. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tufa S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (10): 3530-3539
23. Smithies A (1996) Alpha Interferon in the Treatment of Chronic Myeloid Leukaemia. Southampton: Development and Evaluation Committee, Wessex Institute of Public Health Medicine
24. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338
25. The Chartered Institute of Public Finance and Accountancy (CIPFA) (2000) The Health Service Financial Database and Comparative Tool, Croydon: Institute of Public Finance Ltd
26. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820-825